ADARx Pharmaceuticals Stock

HealthTech

ADARx Pharmaceuticals is a clinical-stage biotechnology company focused on transforming scientific discoveries into life-saving treatments. The company utilizes a proprietary ribonucleic acid (RNA) targeting platform that includes oligonucleotides for inhibition, degradation, and editing, along with innovative oligonucleotide delivery technologies. ADARx Pharmaceuticals is developing an expanding pipeline of RNA-targeting therapeutics aimed at treating a variety of diseases, such as genetic, cardiometabolic, complement-mediated, and central nervous system disorders. This approach enables patients to swiftly treat previously incurable diseases caused by genetic mutations.

Notable investors include: